Evaxion Biotech AS - mit interessanter Pipeline

Einer der wenigen Werte aus dem Biotec-Sektor, die unmittelbar nach dem IPO leicht unter ihren IPO Kurs gefallen sind und somit auch solchen Anlegern eine Einstiegschance geben, die beim IPO nicht zum Zug gekommen sind.

https://evaxion-biotech.com/pipeline/overview/default.aspx

Die Firma hat heute ihr neues Hauptquartier im DTU Science Park in Hoersholm bei Kopenhagen eröffnet :

https://finance.yahoo.com/news/...-office-laboratories-123000826.html

Insgesamt bestehen sehr gute Aussichten, dass man in den kommenden Monaten einiges an News von Evaxion hören wird.

............ ein unerwartetes Schnäppchen ?

Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections.

The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform.

It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery.

The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate.

Evaxion Biotech A/S was founded in 2008 and is headquartered in Copenhagen, Denmark.

............... jetzt sind gute Nerven gefragt

Auf jeden Fall kauft man aktuell 25 % billiger als die Erstzeichner Anfang Februar !

............ schade, dass hier offenbar keiner mitdiskutieren möchte

https://de.marketscreener.com/kurs/aktie/...-118683095/news-historie/

Evaxion Biotech initiated with a Buy, $23 target at Ladenburg

Ladenburg analyst Wangzhi Li initiated coverage of Evaxion Biotech with a Buy rating and $23 price target. Evaxion has built a "top-performing" neoAgs platform and pipeline that may potentially help address some of the current gaps for neoAgs vaccine, with "highly competitive" early clinical results shown, Li tells investors in a research note. The analyst sees the upcoming Phase 1/2 trial readouts in the first half of 2021 for Evaxion's two lead neoAgs vaccine programs as "potential significant near-term catalysts."


Evaxion Biotech initiated with an Outperform at Oppenheimer

Oppenheimer analyst Kevin DeGeeter initiated coverage of Evaxion Biotech with an Outperform rating and $18 price target. DeGeeter expects that Evaxion, a February 2021 IPO, will report important data from EVX-01 and EVX-02 in 2Q21 including durability of response for low-dose EVX-01, T-cell data for high-dose EVX-01 and immunogenicity data for EVX-02, which may serve as an inflection point for shares and offer opportunity for further balance sheet expansion, the analyst tells investors in a research note.